Small Molecules
7 February 2013
Omeros Announces Toxicology Study Data from MASP-2 Inhibitor7 February 2013
Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-7866 February 2013
Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics5 February 2013
Xarelto to be Studied with Factor Xa Inhibitor Antidote5 February 2013
Verastem Initiates Phase 1/1b Clinical Trial of VS-6063 Plus Paclitaxel for Patients with Ovarian Cancer4 February 2013
Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C2 February 2013
Study Concludes That Weight Loss With Qsymia Significantly Improves Multiple Cardiovascular Disease Risk Factors2 February 2013
GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery2 February 2013
Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders31 January 2013
Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer31 January 2013
Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib31 January 2013
Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint31 January 2013
OncoEthix Doses First Patient in its Phase I Trial of OTX015, a BET Bromodomain Inhibitor for the Treatment of Hematologic Malignancies30 January 2013
ADVENTRX Initiates Pivotal Phase 3 Study of ANX-18830 January 2013
Endocyte to Advance Development of EC1069, a PSMA-Targeted Small Molecule Drug Conjugate Therapy for Prostate Cancer30 January 2013
Karolinska Development AB (Publ): Dilaforette – Phase II Study with Sevuparin for the Treatment of Severe Malaria Initiated30 January 2013
FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol for Maintenance Treatment of COPD29 January 2013
Anacor Pharmaceuticals Announces Positive Results From the First of Two Phase 3 Trials of Tavaborole for Onychomycosis29 January 2013
La Jolla Pharmaceutical Company Announces First Patient Treated in Clinical Trial of GCS-100 in Chronic Kidney DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports